Literature DB >> 10982760

Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.

M Sagar1, G Tybring, M L Dahl, L Bertilsson, R Seensalu.   

Abstract

BACKGROUND & AIMS: Omeprazole is metabolized by cytochrome P450 (CYP2C19). The activity of this enzyme is polymorphic, with incidences of poor metabolizers (PMs), heterozygous extensive metabolizers (EMs), and homozygous EMs in white populations of 3%, 30%, and 67%, respectively. The importance of the CYP2C19 polymorphism for the effects of omeprazole on intragastric pH and plasma gastrin concentrations has been investigated.
METHODS: Twenty-five white patients were genotyped for CYP2C19 by allele-specific polymerase chain reaction amplification, and their Helicobacter pylori status was assessed by serology and with immunoblot analysis. Intragastric pH was monitored over 24 hours, and meal-stimulated plasma gastrin concentration was measured over 4 hours (AUC 4h) before (day 0) and during (day 8) treatment with 20 mg omeprazole once daily.
RESULTS: Eleven patients were homozygous for the wild-type allele (wt/wt), 12 were heterozygous EMs (wt/mut), and 2 were PMs (mut/mut). Median (95% confidence interval) 24-hour intragastric pH in the heterozygous EM group was 5.5 (range, 5.1-5. 9) compared with 3.1 (range, 2.7-3.6) in homozygous EMs (P < 0.0001) at day 8. The percentage of time with intragastric pH > 4 at day 8 was significantly higher in the wt/mut than wt/wt group (72.4% vs. 37.1%; P < 0.0001). H. pylori status had less influence than CYP2C19 on intragastric acidity. Omeprazole treatment increased meal-stimulated plasma gastrin concentrations from day 0 to day 8 in the homozygous EMs and heterozygous EMs by 16% (NS) and 157% (P = 0. 002), respectively. In heterozygous EMs, the gastrin increase was more pronounced in the H. pylori-positive group (226%) than H. pylori-negative group (80%; P = 0.02).
CONCLUSIONS: The effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism in patients with acid-related disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982760     DOI: 10.1053/gast.2000.16515

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Non-variceal upper gastrointestinal haemorrhage.

Authors:  I L P Beales
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

2.  A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers.

Authors:  Sandy H Pang; David Y Graham
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

3.  Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Jing Xu; Susumu Tazuma; Yoko Horikawa; Masuo Nakamura
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

Review 4.  Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.

Authors:  Rena Yadlapati; Kelli DeLay
Journal:  Med Clin North Am       Date:  2018-11-01       Impact factor: 5.456

5.  Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.

Authors:  Yongqing Wang; Hongwen Zhang; Ling Meng; Meifeng Wang; Hongyu Yuan; Ning Ou; Haibo Zhang; Ziyan Li; Ruihua Shi
Journal:  Eur J Clin Pharmacol       Date:  2010-04-23       Impact factor: 2.953

Review 6.  Pathogenesis of Helicobacter pylori infection.

Authors:  Johannes G Kusters; Arnoud H M van Vliet; Ernst J Kuipers
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

Review 7.  Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.

Authors:  Bjarni Thjodleifsson
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  Effect of some natural products either alone or in combination on gastritis induced in experimental rats.

Authors:  Mohamed M Elseweidy; Nahla N Younis; Rawia S Amin; Fatma R Abdallah; Azza M Fathy; Zeinab A Yousif
Journal:  Dig Dis Sci       Date:  2008-03-27       Impact factor: 3.199

Review 9.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

10.  Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.

Authors:  Jyh-Chin Yang; Yu-Fan Yang; Yow-Shieng Uang; Chun-Jung Lin; Teh-Hong Wang
Journal:  Br J Clin Pharmacol       Date:  2009-02-23       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.